Work

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-109762

Authors: Farhad Ravandi, Anthony S. Stein, Hagop M. Kantarjian, Roland B. Walter, Peter Paschka, Mojca Jongen-Lavrencic, Gert J. Ossenkoppele, Zhao Yang, Bhakti Mehta, Marion Subklewe

Institutions: The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, City of Hope, Fred Hutch Cancer Center, Universität Ulm, Erasmus MC, Amsterdam University Medical Centers, Amgen (United States), LMU Klinikum, Ludwig-Maximilians-Universität München

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2899502645

Cites:

Cited by: 79

Related to: 10